Abstract
Purpose of Review
Myasthenia gravis (MG) is traditionally conceptualized as a disease with purely motor manifestations. This paper reviews the supporting evidence and pathophysiology of non-motor symptoms in MG, including pain, headache, special sense and autonomic dysfunction, sleep disturbance, and cognitive and psychosocial issues.
Recent Findings
Work in this area has been limited. Recent studies have identified bodily pain and headache as common complaints in patients with MG. A growing literature also suggests that there may be an association of MG and sleep disturbance (both obstructive sleep apnea and sleep cycle dysfunction). Few studies suggest some measurable abnormalities of olfaction, gustation, audition, and autonomic function. The cognitive and psychosocial aspects of MG represent an emerging area of clinical and research interest, but large-scale data is sparse in the USA.
Summary
The pathophysiology of MG is complex, and our understanding of the immunologic basis of this disease is expanding. The classic view of MG as a purely motor disorder may be incomplete. Recent work highlights non-motor symptoms that may impact patient management and quality of life.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
• Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475–90. https://doi.org/10.1016/S1474-4422(09)70063-8. A relevant review of myasthenia gravis.
Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797–810. https://doi.org/10.1056/NEJM199406233302507.
Hughes T. The early history of myasthenia gravis. Neuromuscul Disord. 2005;15(12):878–86. https://doi.org/10.1016/j.nmd.2005.08.007.
• Drachman DB. Myasthenia Gravis. Semin Neurol. 2016;36(5):419–24. https://doi.org/10.1055/s-0036-1586265. Reviews recent advances in the approach to myasthenia gravis.
• Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511–22. https://doi.org/10.1056/NEJMoa1602489. A landmark trial that has demonstrated the benefit of thymectomy in a select group of patients.
Suzuki S, Utsugisawa K, Suzuki N. Overlooked non-motor symptoms in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2013;84(9):989–94. https://doi.org/10.1136/jnnp-2012-304057.
Leon-Sarmiento FE, Leon-Ariza JS, Prada D, Leon-Ariza DS, Rizzo-Sierra CV. Sensory aspects in myasthenia gravis: a translational approach. J Neurol Sci. 2016;368:379–88. https://doi.org/10.1016/j.jns.2016.07.014.
Lloyd JM, Mitchell RG. Myasthenia gravis as a cause of facial pain. Oral Surg Oral Med Oral Pathol. 1988;66(1):45–6.
• Scott KR, Kothari MJ. Self-reported pain affects quality of life in myasthenia gravis. J Clin Neuromuscul Dis. 2006;7(3):110–4. https://doi.org/10.1097/01.cnd.0000202223.39994.c0. One of few available papers that focuses on this important issue in the management of MG.
Padua L, Evoli A, Aprile I, Caliandro P, D'Amico P, Rabini A, et al. Quality of life in patients with myasthenia gravis. Muscle Nerve. 2002;25(3):466–7.
Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ. 1993;306(6890):1440–4.
Mullins LL, Carpentier MY, Paul RH, Sanders DB, Muscle Study G. Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve. 2008;38(2):947–56. https://doi.org/10.1002/mus.21016.
Muppidi S. The myasthenia gravis—specific activities of daily living profile. Ann N Y Acad Sci. 2012;1274:114–9. https://doi.org/10.1111/j.1749-6632.2012.06817.x.
Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav. 1984;32(3):489–502.
Leon-Sarmiento FE, Bayona EA, Bayona-Prieto J, Osman A, Doty RL. Profound olfactory dysfunction in myasthenia gravis. PLoS One. 2012;7(10):e45544. https://doi.org/10.1371/journal.pone.0045544.
Tekeli H, Senol MG, Altundag A, Yalcinkaya E, Kendirli MT, Yasar H, et al. Olfactory and gustatory dysfunction in myasthenia gravis: a study in Turkish patients. J Neurol Sci. 2015;356(1–2):188–92. https://doi.org/10.1016/j.jns.2015.06.054.
Castillo PE, Carleton A, Vincent JD, Lledo PM. Multiple and opposing roles of cholinergic transmission in the main olfactory bulb. J Neurosci. 1999;19(21):9180–91.
Ralli M, Altissimi G, Di Stadio A, Mazzei F, Turchetta R, Cianfrone G. Relationship between hearing function and myasthenia gravis: a contemporary review. J Int Med Res. 2017;45(5):1459–65. https://doi.org/10.1177/0300060516672124.
Dallos P, He DZ, Lin X, Sziklai I, Mehta S, Evans BN. Acetylcholine, outer hair cell electromotility, and the cochlear amplifier. J Neurosci. 1997;17(6):2212–26.
Toth L, Racz T, Dioszeghy P, Repassy G, Lampe I. Otoacoustic emission in myasthenia gravis patients and the role of efferent activation. Hear Res. 1998;126(1–2):123–5.
Paludetti G, Di Nardo W, D'Ecclesia A, Evoli A, Scarano E, Di Girolamo S. The role of cholinergic transmission in outer hair cell functioning evaluated by distortion product otoacoustic emissions in myasthenic patients. Acta Otolaryngol. 2001;121(2):119–21.
Cull RE. Unilateral headache due to myasthenia gravis. Cephalalgia. 2003;23(7):556–7. https://doi.org/10.1046/j.1468-2982.2003.00513.x.
Nishimoto Y, Suzuki S, Utsugisawa K, Nagane Y, Shibata M, Shimizu T, et al. Headache associated with myasthenia gravis: the impact of mild ocular symptoms. Autoimmune Dis. 2011;2011:840364. https://doi.org/10.4061/2011/840364.
• Oliveira EF, Nacif SR, Urbano JJ, Silva AS, Oliveira CS, Perez EA, et al. Sleep, lung function, and quality of life in patients with myasthenia gravis: a cross-sectional study. Neuromuscul Disord. 2017;27(2):120–7. https://doi.org/10.1016/j.nmd.2016.11.015. Addresses major sleep-related issues in MG patients, an often under-addressed topic.
Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400–6. https://doi.org/10.1212/01.wnl.0000312374.95186.cc.
Ponseti JM, Gamez J, Azem J, Lopez-Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci. 2008;1132:254–63. https://doi.org/10.1196/annals.1405.000.
Davies A, Merli F, Mihaljevic B, Mercadal S, Siritanaratkul N, Solal-Celigny P, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6):e272–e82. https://doi.org/10.1016/S2352-3026(17)30078-9.
• Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017; https://doi.org/10.1016/S1474-4422(17)30369-1. A newly approved medication for treatment of MG.
Weissert R. Progressive multifocal leukoencephalopathy. J Neuroimmunol. 2011;231(1–2):73–7. https://doi.org/10.1016/j.jneuroim.2010.09.021.
Marie I, Cherin P, Michallet M, Pelus E, Dantal J, Crave JC, et al. Management of adverse effects related to human immunoglobulin therapy: recommendations for clinical practice. Rev Med Interne. 2016;38:312–9. https://doi.org/10.1016/j.revmed.2016.10.390.
Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121(4):259–62.
Thornby KA, Henneman A, Brown DA. Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches. Ann Pharmacother. 2015;49(6):715–26. https://doi.org/10.1177/1060028015576362.
Pascuzzi RM. Medications and myasthenia gravis. Myasthenia Gravis Foundation of America, Inc. 2007. http://www.myasthenia.org/LinkClick.aspx?fileticket=JuFvZPPq2vg%3D.
Haroutiunian S, Lecht S, Zur AA, Hoffman A, Davidson E. The challenge of pain management in patients with myasthenia gravis. J Pain Palliat Care Pharmacother. 2009;23(3):242–60. https://doi.org/10.1080/15360280903098523.
Scheschonka A, Beuche W. Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. Pain. 2003;104(1–2):423–4.
Sheen VL, Ohaegbulam C, Rencus T, Tandon D. Gabapentin-induced exacerbation of myasthenia gravis. Muscle Nerve. 2010;42(1):149. https://doi.org/10.1002/mus.21708.
Boneva N, Brenner T, Argov Z. Gabapentin may be hazardous in myasthenia gravis. Muscle Nerve. 2000;23(8):1204–8.
Bashuk RG, Krendel DA. Myasthenia gravis presenting as weakness after magnesium administration. Muscle Nerve. 1990;13(8):708–12. https://doi.org/10.1002/mus.880130808.
Nikolic A, Peric S, Nisic T, Popovic S, Ilic M, Stojanovic VR, et al. The presence of dysautonomia in different subgroups of myasthenia gravis patients. J Neurol. 2014;261(11):2119–27. https://doi.org/10.1007/s00415-014-7465-x.
Shukla G, Gupta S, Goyal V, Singh S, Srivastava A, Behari M. Abnormal sympathetic hyper-reactivity in patients with myasthenia gravis: a prospective study. Clin Neurol Neurosurg. 2013;115(2):179–86. https://doi.org/10.1016/j.clineuro.2012.05.013.
Peltier AC, Black BK, Raj SR, Donofrio P, Robertson D, Biaggioni I. Coexistent autoimmune autonomic ganglionopathy and myasthenia gravis associated with non-small-cell lung cancer. Muscle Nerve. 2010;41(3):416–9. https://doi.org/10.1002/mus.21528.
Vernino S, Cheshire WP, Lennon VA. Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci. 2001;88(3):187–92. https://doi.org/10.1016/S1566-0702(01)00239-9.
Martinez-Lapiscina EH, Erro ME, Ayuso T, Jerico I. Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle Nerve. 2012;46(2):174–80. https://doi.org/10.1002/mus.23296.
Jordan B, Schweden TL, Mehl T, Menge U, Zierz S. Cognitive fatigue in patients with myasthenia gravis. Muscle Nerve. 2016; https://doi.org/10.1002/mus.25540.
Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002;165(9):1217–39.
Nicolle MW, Rask S, Koopman WJ, George CF, Adams J, Wiebe S. Sleep apnea in patients with myasthenia gravis. Neurology. 2006;67(1):140–2. https://doi.org/10.1212/01.wnl.0000223515.15691.26.
Prudlo J, Koenig J, Ermert S, Juhasz J. Sleep disordered breathing in medically stable patients with myasthenia gravis. Eur J Neurol. 2007;14(3):321–6. https://doi.org/10.1111/j.1468-1331.2006.01666.x.
Papazian O. Rapid eye movement sleep alterations in myasthenia gravis. Neurology. 1976;26(4):311–6.
Keesey JC. Does myasthenia gravis affect the brain? J Neurol Sci. 1999;170(2):77–89.
Sieminski M, Bilinska M, Nyka WM. Increased frequency of restless legs syndrome in myasthenia gravis. Eur Neurol. 2012;68(3):166–70. https://doi.org/10.1159/000339485.
Whiting PJ, Cooper J, Lindstrom JM. Antibodies in sera from patients with myasthenia gravis do not bind to nicotinic acetylcholine receptors from human brain. J Neuroimmunol. 1987;16(2):205–13.
Keesey JC, Tourtellotte WW, Herrmann C Jr, Andrews JM, Lindstrom J. Acetylcholine-receptor antibody in cerebrospinal fluid. Lancet. 1978;1(8067):777.
Lefvert AK, Pirskanen R. Acetylcholine-receptor antibodies in cerebrospinal fluid of patients with myasthenia gravis. Lancet. 1977;2(8033):351–2.
Paul RH, Cohen RA, Gilchrist JM, Aloia MS, Goldstein JM. Cognitive dysfunction in individuals with myasthenia gravis. J Neurol Sci. 2000;179(S 1–2):59–64.
Mao Z, Yin J, Lu Z, Hu X. Association between myasthenia gravis and cognitive function: a systematic review and meta-analysis. Ann Indian Acad Neurol. 2015;18(2):131–7. https://doi.org/10.4103/0972-2327.156560.
Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress ME, Yaldoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology. 1996;47(6):1396–402.
Paul RH, Cohen RA, Zawacki T, Gilchrist JM, Aloia MS. What have we learned about cognition in myasthenia gravis?: a review of methods and results. Neurosci Biobehav Rev. 2001;25(1):75–81.
Kluger BM, Krupp LB, Enoka RM. Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. Neurology. 2013;80(4):409–16. https://doi.org/10.1212/WNL.0b013e31827f07be.
Symonette CJ, Watson BV, Koopman WJ, Nicolle MW, Doherty TJ. Muscle strength and fatigue in patients with generalized myasthenia gravis. Muscle Nerve. 2010;41(3):362–9. https://doi.org/10.1002/mus.21493.
Aysal F, Karamustafalioglu O, Ozcelik B, Yilmaz M, Karamustafalioglu N, Yumrukcal H, et al. The relationship of symptoms of anxiety and depression with disease severity and treatment modality in myasthenia gravis: a cross-sectional study. Noro Psikiyatr Ars. 2013;50(4):295–300. https://doi.org/10.4274/npa.y5611.
Paradis CM, Friedman S, Lazar RM, Kula RW. Anxiety disorders in a neuromuscular clinic. Am J Psychiatry. 1993;150(7):1102–4. https://doi.org/10.1176/ajp.150.7.1102.
Suzuki Y, Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Kabasawa C, et al. Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. BMJ Open. 2011;1(2):e000313. https://doi.org/10.1136/bmjopen-2011-000313.
Hoffman R, Grittner K, Siedler M. Fatigue in myasthenic gravis: risk factors and impact on quality of life. Brain Behav. 2016;6(10):e00538. https://doi.org/10.1002/brb3.538.
Nagane Y, Murai H, Imai T, Yamamoto D, Tsuda E, Minami N, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7(2):e013278. https://doi.org/10.1136/bmjopen-2016-013278.
Chen YT, Shih FJ, Hayter M, Hou CC, Yeh JH. Experiences of living with myasthenia gravis: a qualitative study with Taiwanese people. J Neurosci Nurs. 2013;45(2):E3–E10. https://doi.org/10.1097/JNN.0b013e31828291a6.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Olivia Tong, Leslie Delfiner, and Steven Herskovitz declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Secondary Headache
Rights and permissions
About this article
Cite this article
Tong, O., Delfiner, L. & Herskovitz, S. Pain, Headache, and Other Non-motor Symptoms in Myasthenia Gravis. Curr Pain Headache Rep 22, 39 (2018). https://doi.org/10.1007/s11916-018-0687-3
Published:
DOI: https://doi.org/10.1007/s11916-018-0687-3